Owkin has launched a biological ai agent, which is being used in conjunction with Anthropic's Claude, for applications in healthcare and life sciences. The agent is intended to support clinical research and drug discovery, with the goal of improving the efficiency of these processes. The launch is part of a broader effort to apply ai to biology, with Owkin also announcing a license agreement with AstraZeneca and unveiling its agentic ai infrastructure.